DOVA News and Press, Dova Pharmaceuticals Inc. From 03/05/19

DURHAM, N.C., March 05, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the Cowen and Company 39 th Annual Health Care Conference on Wednesday, March 13,...

Dova Pharmaceuticals, Inc. (DOVA) Q4 2018 Earnings Conference Call March 5, 2019 9:00 AM ET Company Participants David Zaccardelli – President and Chief Executive Officer Mark Hahn – Chief Financial Officer Kevin Laliberte – Vice President-Product Development...

Dova Pharmaceuticals (NASDAQ: DOVA ): Q4 GAAP EPS of -$0.69 beats by $0.09 . More news on: Dova Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...

DOPTELET ® (avatrombopag) approved May 21, 2018 and launched June 4, 2018 Net product sales from DOPTELET were $2.8 million in the fourth quarter of 2018 and $7.7 million for the full year ended December 31, 2018 sNDA accepted for review by FDA for DOPTELET for the treatment ...

Last year, right around Dova Pharmaceuticals’ ( DOVA ) PDUFA for Doptelet, we made a bit of money in the stock. But we held on too long to some of the shares, and ended up losing what we made. Dova is in a bad position today, having shed over 70% of its value since approval last year ...

DURHAM, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, March 5, 2019 at 9:00 a.m. ET to discuss fourth quarter and full year 2018 financial results and recent operational highlights. A question-and-answer session wil...

DURHAM, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the 8 th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 ...